These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 29284347)

  • 1. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
    Henk HJ; Woloj M; Shapiro M; Whiteley J
    Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
    Kreys ED; Frei CR; Villarreal SM; Bollinger MJ; Jones X; Koeller JM
    Pharmacotherapy; 2017 Mar; 37(3):278-286. PubMed ID: 28052354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
    Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
    [No Abstract]   [Full Text] [Related]  

  • 8. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
    Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
    J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.
    Di Bella NJ; Bhowmik D; Bhor M; Yap M; Middlebrook B; Rembert D; Cain Z; Okoro T; Bolinder B; Patt D; Jabbour EJ
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):599-605. PubMed ID: 26208445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
    Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I
    Cancer Sci; 2020 Oct; 111(10):3714-3725. PubMed ID: 33404088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
    Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
    Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
    Bettiol A; Marconi E; Lombardi N; Crescioli G; Gherlinzoni F; Walley T; Vannacci A; Chinellato A; Giusti P
    Clin Drug Investig; 2018 Sep; 38(9):837-844. PubMed ID: 30043130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
    Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
    J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
    Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
    Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
    Kenzik KM; Bhatia R; Bhatia S
    JAMA Oncol; 2020 Apr; 6(4):542-546. PubMed ID: 31999305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
    Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
    Iurlo A; Orsi E; Cattaneo D; Resi V; Bucelli C; Orofino N; Sciumè M; Elena C; Grancini V; Consonni D; Orlandi EM; Cortelezzi A
    Oncotarget; 2015 Oct; 6(32):33944-51. PubMed ID: 26376678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.